


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claim 1 (Currently Amended) A quinazoline derivative having the following formula (1) and
or a pharmaceutically acceptable salt thereof:



wherein the ring A represents an aryl group:

R¹ represents (a) hydroxyl group, (b) an amino group, (c) a C₁ to C₄ lower alkylamino group which may be substituted with a COOH group, (d) a C₇ and C₁₀ lower aralkylamino group which may be substituted with a COOH group, (e) an amino group acylated with a C₁ to C₄ lower aliphatic acid which may be substituted with a COOH group, (f) an amino group acylated with an aromatic ring carboxylic acid which may be substituted with a COOH group, (g) an amino group acylated with a heteroaromatic ring carboxylic acid which may be substituted with a COOH group, (h) an amino group sulfonylated with a C₁ to C₄ lower alkanesulfonic acid which may be substituted with a COOH group, (i) an amino group sulfonylated with an aromatic ring sulfonic acid which may be substituted with a COOH group, (j) an amino group sulfonylated with a heteroaromatic ring sulfonic acid which may be substituted with a COOH group, (k) a C₁ to C₄ lower alkyl group substituted with a COOH group, or (l) a C₂ to C₄ lower alkenyl group which may be substituted with a COOH group;

R² and R³ may be the same or different and represent (a) a hydrogen atom, (b) an unsubstituted or substituted a C₁ to C₄ lower alkyl group which may be substituted with a COOH

group, a halogen atom, a C₁ to C₄ lower alkoxy group, an amino group, a methylamino group, a dimethylamino group, a carboxymethylamino group or a carboxyethylamino group, (c) a halogen atom, (d) a hydroxyl group, (e) a C₁ to C₄ lower alkoxy group, (f) an amino group, (g) an unsubstituted or substituted a C₁ to C₄ lower alkylamino group which may be substituted with a COOH group, a halogen atom or a C₁ to C₄ lower alkoxy group, (h) an unsubstituted or substituted C₄ to C₁₀ a C₇ to C₁₂ aralkylamino group which may be substituted with a COOH group, a halogen atom or a C₁ to C₄ lower alkoxy group, (i) an amino group acylated with a C₁ to C₄ lower aliphatic acid which may be substituted with a COOH group, (j) an amino group acylated with an aromatic ring carboxylic acid which may be substituted with a COOH group, (k) an amino group acylated with a heteroaromatic ring carboxylic acid which may be substituted with a COOH group, (l) an amino group sulfonylated with a C₁ to C₄ lower alkanesulfonic acid which may be substituted with a COOH group, (m) an amino group sulfonylated with an aromatic ring sulfonic acid which may be substituted with a COOH group, (n) an amino group sulfonylated with a heteroaromatic ring sulfonic acid which may be substituted with a COOH group, or (o) a COOH group or

when the ring A is benzene ring, R¹ and R² may form, together with the substituting benzene ring, (a) a tetrahydroquinoline ring or (b) a benzoxazine ring which may be substituted with a COOH group and in which the carbon atom in the ring may form a carbonyl group and R³ is the same as defined above; and

X represents (a) a hydrogen atom, (b) a C₁ to C₄ lower alkyl group, (c) a C₁ to C₄ lower alkoxy group, (d) a halogen atom, (e) a hydroxyl group, (e) an amino group, or (g) a nitro group, with the proviso that, when A is a benzene ring and R¹ is an amino group, R² and R³ are not a hydrogen atom at the same time.

Claim 2 (Previously Presented) A quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 1, wherein, in the formula (1), R¹ is a hydroxyl group, an amino group, a C₁ to C₄ lower alkylamino group substituted with a COOH group, or an amino group acylated with a C₁ to C₄ lower aliphatic acid substituted with a COOH group.

Claim 3 (Previously Presented) A quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 1, wherein, in the formula (1), R² is a COOH group or a hydrogen atom.

Claim 4 (Previously Presented) A quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 1, wherein R³ in the formula (I) is a hydrogen atom.

Claim 5 (Previously Presented) A pharmaceutical composition comprising as an effective ingredient a pharmaceutically effective amount of a quinazoline derivative or the pharmaceutically acceptable salt thereof according to claim 1 and a pharmaceutically acceptable carrier therefor.

Claim 6 (Previously Presented) A chymase inhibitor having as an effective ingredient a quinazoline derivative or its pharmaceutically salt according to claim 1, and a pharmaceutically acceptable carrier therefor.

Claims 7-13 (Canceled)

Claim 14 (Currently Amended) A method for treatment of allergic diseases or rheumatic diseases comprising administering to a patient in need of such prevention or treatment an effective amount of a quinazoline derivative or salt thereof according to claim 1.

Claim 15 (Currently Amended) A method for treatment of bronchial asthma, eczema, atopic dermatitis, mastocytosis, scleriosis or rheumatoid arthritis comprising administering to a patient in need of such prevention or treatment an effective amount of a quinazoline derivative or salt thereof according to claim 1.

Claim 16 (Currently Amended) A method for treatment of cardiac and circulatory system diseases due to the abnormal exacerbation of Angiotensin II production comprising administering to a patient in need of such prevention or treatment an effective amount of a quinazoline derivative or salt thereof according to claim 1.

Claim 17 (Currently Amended) A method for treatment of cardiac insufficiency, hypercardia, stasis cardiac diseases, hypertension, arteriosclerosis, peripheral circulatory diseases,

revasoconstriction after PTCA, diabetic renal disorders or non-diabetic renal disorders, coronary diseases including cardiac infarction, angioendothelia or vascular disorders accompanying arterialization and atheroma comprising administering to a patient in need of such ~~prevention or~~ treatment an effective amount of a quinazoline derivative or salt thereof according to claim 1.

Claim 18 (Currently Amended) A quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 2, wherein, in the formula (1), R^2 is a ~~carboxylic acid~~ COOH group or a hydrogen atom.

Claim 19 (Currently Amended) A quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 18, wherein R^3 in the formula (1), R^2 is a hydrogen atom.

E1
Claim 20 (Previously Presented) A pharmaceutical composition comprising as an effective ingredient a pharmaceutically effective amount of a quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 2, and a pharmaceutically acceptable carrier therefor.

Claim 21 (Previously Presented) A pharmaceutical composition comprising as an effective ingredient a pharmaceutically effective amount of a quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 3, and a pharmaceutically acceptable carrier therefor.


Claim 22 (Previously Presented) A pharmaceutical composition comprising as an effective ingredient a pharmaceutically effective amount of a quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 4, and a pharmaceutically acceptable carrier therefor.

Claim 23 (Previously Presented) A pharmaceutical composition comprising as an effective ingredient a pharmaceutically effective amount of a quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 18, and a pharmaceutically acceptable carrier therefor.

Claim 24 (Previously Presented) A pharmaceutical composition comprising as an effective ingredient a pharmaceutically effective amount of a quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 19, and a pharmaceutically acceptable carrier therefor.

Claim 25 (Canceled)

Claim 26 (New) A quinazoline derivative having the following formula (1) and a pharmaceutically acceptable salt thereof:



wherein the ring A represents an aryl group:

E1
 R^1 represents (a) hydroxyl group, (b) an amino group, (c) a C_1 to C_4 lower alkylamino group which may be substituted with a COOH group, (d) a C_7 and C_{10} lower aralkylamino group which may be substituted with a COOH group, (e) an amino group acylated with a C_1 to C_4 lower aliphatic acid which may be substituted with a COOH group, (f) an amino group acylated with an aromatic ring carboxylic acid which may be substituted with a COOH group, (g) an amino group acylated with a heteroaromatic ring carboxylic acid which may be substituted with a COOH group, (h) an amino group sulfonylated with a C_1 to C_4 lower alkanesulfonic acid which may be substituted with a COOH group, (i) an amino group sulfonylated with an aromatic ring sulfonic acid which may be substituted with a COOH group, (j) an amino group sulfonylated with a heteroaromatic ring sulfonic acid which may be substituted with a COOH group, (k) a C_1 to C_4 lower alkyl group substituted with a COOH group, or (l) a C_2 to C_4 lower alkenyl group which may be substituted with a COOH group;

R^2 and R^3 may be the same or different and represent (a) a hydrogen atom, (b) a C_1 to C_4 lower alkyl group which may be substituted with a COOH group, a halogen atom, a C_1 to C_4 lower alkoxy group, an amino group, a methylamino group, a dimethylamino group, a carboxymethylamino group or a carboxyethylamino group, (c) a halogen atom, (d) a hydroxyl group, (e) a C_1 to C_4 lower alkoxyl group, (f) an amino group, (g) a C_1 to C_4 lower alkylamino group which may be substituted with a COOH group, a halogen atom or a C_1 to C_4 lower alkoxy group, (h) a C_7 to C_{12} aralkylamino

group which may be substituted with a COOH group, a halogen atom or a C₁ to C₄ lower alkoxy group, (i) an amino group acylated with a C₁ to C₄ lower aliphatic acid which may be substituted with a COOH group, (j) an amino group acylated with an aromatic ring carboxylic acid which may be substituted with a COOH group, (k) an amino group acylated with a heteroaromatic ring carboxylic acid which may be substituted with a COOH group, (l) an amino group sulfonylated with a C₁ to C₄ lower alkanesulfonic acid which may be substituted with a COOH group, (m) an amino group sulfonylated with an aromatic ring sulfonic acid which may be substituted with a COOH group, (n) an amino group sulfonylated with a heteroaromatic ring sulfonic acid which may be substituted with a COOH group, or (o) a COOH group or

E 1 when the ring A is benzene ring, R¹ and R² may form, together with the substituting benzene ring, (a) a tetrahydroquinoline ring or (b) a benzoxazine ring which may be substituted with a COOH group and in which the carbon atom in the ring may form a carbonyl group and R³ is the same as defined above; and

X represents (a) a hydrogen atom, (b) a C₁ to C₄ lower alkyl group, (c) a C₁ to C₄ lower alkoxy group, (d) a halogen atom, (e) a hydroxyl group, (e) an amino group, or (g) a nitro group, with the proviso that, when A is a benzene ring and R¹ is an amino group, R² and R³ are not a hydrogen atom at the same time,

wherein when A is a benzene ring and

R¹ represents an amino group,

R² and R³ are different and represent a hydrogen atom, an unsubstituted or a substituted C₁ to C₄ lower alkyl group which may be substituted with a COOH group, a C₁ to C₄ lower alkoxy group or a COOH group,

or

R² and R³ each represent a hydrogen atom.

Claim 27 (New) A quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 26, wherein A is a benzene ring,

R¹ represents an amino group, and

R² and R³ are different and represent a hydrogen atom, a C₁ to C₄ lower alkyl group which may be substituted with a COOH group, a C₁ to C₄ lower alkoxy group or a COOH group.

Claim 28 (New) A quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 26, wherein A is a benzene ring,

R¹ represents an amino group, and

R² and R³ each represent a hydrogen atom.

Claim 29 (New) A quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 26, wherein said compound is selected from the group consisting of

3-(4-amino-3,5-dichlorobenzenesulfonyl)-7-chloro-2,4(1H,3H)-quinazolinedione,

3-(3-amino-4-methylbenzenesulfonyl)-7-chloro-2,4(1H,3H)-quinazolinedione,

4-[(7-chloro-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]anthranilic acid,

4-[(7-chloro-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]anthranilic acid monosodium salt,

3-(3-amino-4-methoxybenzenesulfonyl)-7-chloro-2,4(1H,3H)-quinazolinedione,


5-[(7-chloro-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]anthranilic acid,

4-[(7-methoxy-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]anthranilic acid,

4-[(7-hydroxy-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]anthranilic acid and

4-[(6-chloro-2,4(1H,3H)-quinazolinedion-3-yl)sulfonyl]anthranilic acid.

Claim 30 (New) A quinazoline derivative having the following formula (1) or a pharmaceutically acceptable salt thereof:



wherein the ring A represents an aryl group:

R¹ is a hydroxyl group, an amino group, a C₁ to C₄ lower alkylamino group substituted with a COOH group, or an amino group acylated with a C₁ to C₄ lower aliphatic acid substituted with a COOH group,

E1 R² is (1) a C₁ to C₄ lower alkyl group which may be substituted with a COOH group, a halogen atom, a C₁ to C₄ lower alkoxy group, an amino group, a methylamino group, a dimethylamino group, a carboxymethylamino group or a carboxyethylamino group, (2) a halogen atom, (3) a hydroxyl group, (4) a C₁ to C₄ lower alkoxy group, (5) an amino group, (6) a C₁ to C₄ lower alkylamino group which may be substituted with a COOH group, a halogen atom or a C₁ to C₄ lower alkoxy group, (7) a C₇ to C₁₂ aralkylamino group which may be substituted with a COOH group, a halogen atom or a C₁ to C₄ lower alkoxy group, (8) an amino group acylated with a C₁ to C₄ lower aliphatic acid which may be substituted with a COOH group, (9) an amino group acylated with an aromatic ring carboxylic acid which may be substituted with a COOH group, (10) an amino group acylated with a heteroaromatic ring carboxylic acid which may be substituted with a COOH group, (11) an amino group sulfonated with a C₁ to C₄ lower alkanesulfonic acid which may be substituted with a COOH group, (12) an amino group sulfonated with an aromatic ring sulfonic acid which may be substituted with a COOH group, (13) an amino group sulfonated with a heteroaromatic ring sulfonic acid which may be substituted with a COOH group, or (14) a COOH group, and

R³ is (a) a hydrogen atom, (b) a C₁ to C₄ lower alkyl group which may be substituted with a COOH group, a halogen atom, a C₁ to C₄ lower alkoxy group, an amino group, a methylamino group, a dimethylamino group, a carboxymethylamino group or a carboxyethylamino group, (c) a halogen

atom, (d) a hydroxyl group, (e) a C₁ to C₄ lower alkoxy group, (f) an amino group, (g) a C₁ to C₄ lower alkylamino group which may be substituted with a COOH group, a halogen atom or a C₁ to C₄ lower alkoxy group, (h) a C₇ to C₁₂ aralkylamino group which may be substituted with a COOH group, a halogen atom or a C₁ to C₄ lower alkoxy group, (i) an amino group acylated with a C₁ to C₄ lower aliphatic acid which may be substituted with a COOH group, (j) an amino group acylated with an aromatic ring carboxylic acid which may be substituted with a COOH group, (k) an amino group acylated with a heteroaromatic ring carboxylic acid which may be substituted with a COOH group, (l) an amino group sulfonylated with a C₁ to C₄ lower alkanesulfonic acid which may be substituted with a COOH group, (m) an amino group sulfonylated with an aromatic ring sulfonic acid which may be substituted with a COOH group, (n) an amino group sulfonylated with a heteroaromatic ring sulfonic acid which may be substituted with a COOH group, or (o) a COOH group or

when the ring A is benzene ring, R¹ and R² may form, together with the substituting benzene ring, (a) a tetrahydroquinoline ring or (b) a benzoxazine ring which may be substituted with a COOH group and in which the carbon atom in the ring may form a carbonyl group and R³ is the same as defined above; and

X represents (a) a hydrogen atom, (b) a C₁ to C₄ lower alkyl group, (c) a C₁ to C₄ lower alkoxy group, (d) a halogen atom, (e) a hydroxyl group, (e) an amino group, or (g) a nitro group.

Claim 31 (New) A quinazoline derivative or a pharmaceutically acceptable salt thereof as claimed in claim 30, wherein, in the formula (1), R² is a COOH group.